Aurobindo Pharma: USFDA Closes Raleigh Inspection, Regulatory Clarity Improves
Aurobindo Pharma Ltd is likely to remain in focus after its Raleigh, North Carolina facility received the Establishment Inspection Report (EIR) from the USFDA, bringing the inspection to a close. The facility, operated by Aurolife Pharma LLC, a wholly owned step-down subsidiary, was inspected between March 24 and April 10, 2025, and manufactures inhalers, dermatology and transdermal products.
The inspection had resulted in 11 observations through Form 483. The subsequent EIR classified the facility as “Voluntary Action Indicated” (VAI), which closes the inspection and allows pending applications for multiple inhalers and other dosage forms from the facility to progress through the USFDA review process.
From an investor perspective, the development is constructive as it provides greater regulatory clarity for the site and reduces uncertainty around the progress of pending product applications. However, the VAI classification also means continued compliance remains important, and the impact on earnings will ultimately depend on the regulatory progress and commercialisation of the affected products.